The National Institute on Drug Abuse (NIDA) awarded a $643,978 Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to See Yourself Health LLC, a woman-owned small business in Beverly, MA. The grant titled "The CHIRON Project: Using Virtual Reality to Prevent Substance Use Disorder in Healthcare Workers Facing Burnout" aims to develop an immersive virtual reality platform that enables healthcare professionals to access confidential peer support, evidence-based...
The National Institute on Drug Abuse (NIDA) awarded a $1,076,018 Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to Dynamicare Health Inc. in Wareham, MA. The award will fund a Phase II randomized clinical trial to evaluate the efficacy of DCH-003, a digital therapeutic that delivers contingency management for the treatment of stimulant use disorder. The trial will compare standard clinic care plus DCH-003 to standard care plus a sham digital app, with the...
This $671,310 Project Grant award from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) supports the development of novel therapeutic agents for the treatment of Stimulant Use Disorder (STUD). The awardee, Verisim Life, Inc., is leveraging its proprietary AI-driven drug discovery platform, BioiSim, to expedite the development of STUD drug candidates with favorable pharmacokinetic, pharmacodynamic, and safety profiles. The key goals of...
The National Institute on Drug Abuse (NIDA) awarded a $306,528 Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to Addinex Technologies, Inc. The grant will fund the development of a medication adherence and monitoring system to support decentralized clinical trials for substance use disorder (SUD). The project aims to adapt Addinex's existing medication management system to provide researchers running SUD clinical trials with a tool for at-home dispensing that...
This Project Grant award of $591,032 was provided by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) to Square2 Systems Inc. in Hanover, NH. The funding will support the development of the "COGITO" platform, a turnkey solution for rapidly developing, evaluating, deploying, and scaling digital therapeutics for the prevention, treatment, and management of substance use disorders and other behavioral health conditions. The...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), aims to validate a virtual reality-based attentional bias (VR-AB) marker as a biomarker for tobacco use disorder. The $1,766,843 award will fund a study to assess the VR-AB marker's reliability, its potential as a predictive biomarker for response to the smoking cessation medication varenicline, and its viability as a candidate surrogate endpoint. The...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $406,451.00 to Ksana Health Inc. to develop and refine the VIRA mobile app platform as an adjunctive treatment for opioid use disorder (OUD). The key products and services to be delivered include: Technical development and user-centered research to extend the VIRA platform's capabilities to provide just-in-time interventions for two types of cues...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $608,046 to Evidation Health, Inc. to develop a digital product called "Research and Engagement on Substance Use Harnessing Awareness and Personalized Education (RESHAPE)". The objective is to create a comprehensive digital experience to improve well-being and self-efficacy for individuals with substance use disorder (SUD) and...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the federal Drug Use and Addiction Research Programs (CFDA 93.279), provides $304,215 to Carina Medical LLC to develop and validate a novel software platform for decentralized clinical trials (DCTs) in substance use disorder (SUD). The project aims to leverage large language models (LLMs) to automate data collection and improve efficiency and accuracy for SUD DCTs. Key objectives include developing the software...
This Project Grant award of $397,829 from the National Institute on Drug Abuse (NIDA), under the federal Drug Use and Addiction Research Programs (CFDA 93.279), supports the development of an AI platform to discover new therapeutics for substance use disorders (SUDs). The key products and services to be delivered include: Creating a set of curated training datasets and machine learning (ML) models to accelerate drug discovery tasks for SUDs. Identifying mechanistic targets related to the...
The National Institute on Drug Abuse (NIDA) awarded a $959,964 Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to Charles River Analytics, Inc. to design and demonstrate the feasibility of a prototype system called Stimulant Use Recovery via Immersive Virtual Environments (SURVIVE). The goal of SURVIVE is to provide controlled environmental triggers and cognitive behavioral therapy (CBT) embedded into virtual environments to treat stimulant use disorder (STUD), which includes the misuse of methamphetamine, cocaine, and other amphetamines. The project aims to leverage virtual reality technology to improve access to CBT treatment, increase patient engagement, and provide clinicians with tools to personalize treatment and validate the effectiveness of using a virtual environment for CBT. The award period runs from September 30, 2024 to September 29, 2025.